The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement

Diagnostic Cytopathology

Volumn 34, Issue 12, 2006, Pages 801-806

  Saad, Reda S ^a   Lindner, Jennifer L ^b   Lin, Xiaoqi ^b   Liu, Yulin L ^a   Silverman, Jan F ^a  

^a DREXEL UNIVERSITY COLLEGE OF MEDICINE   (United States)

^b ALLEGHENY GENERAL HOSPITAL   (United States)

Author keywords

Adenocarcinoma; D2 40; Effusion cytology; Malignant mesothelioma

Indexed keywords

CALRETININ; CYTOKERATIN 5; CYTOKERATIN 6; FORMALDEHYDE; PARAFFIN; PROTEIN D2 40; PROTEIN P63; THYROID TRANSCRIPTION FACTOR 1; TUMOR MARKER; WT1 PROTEIN;

ARTICLE; CYTODIAGNOSIS; DIAGNOSTIC VALUE; DIFFERENTIAL DIAGNOSIS; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; LUNG ADENOCARCINOMA; LUNG CARCINOMA; MALIGNANT MESOTHELIOMA; PLEURA EFFUSION; PLEURA FLUID; PRIORITY JOURNAL; SENSITIVITY AND SPECIFICITY; SQUAMOUS CELL CARCINOMA;

AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL; CALCIUM-BINDING PROTEIN, VITAMIN D-DEPENDENT; DNA-BINDING PROTEINS; FEMALE; GENE EXPRESSION REGULATION, NEOPLASTIC; HUMANS; IMMUNOHISTOCHEMISTRY; KERATIN-5; LUNG NEOPLASMS; MALE; MEMBRANE PROTEINS; MESOTHELIOMA; MIDDLE AGED; PLEURAL NEOPLASMS; SENSITIVITY AND SPECIFICITY; TUMOR MARKERS, BIOLOGICAL; WT1 PROTEINS;

EID: 33845440791     PISSN: 87551039     EISSN: 10970339     Source Type: Journal    
DOI: 10.1002/dc.20556     Document Type: Article

References (42)

1. Taub RN, Keohan ML, Chabot JC, Fountain KS, Plitsas M. Peritoneal mesothelioma. Curr Treat Options Oncol 2000;1:303-312.
2. Zellos LS, Sugarbaker DJ. Diffuse malignant mesothelioma of the pleural space and its management. Oncology 2002;87:907-713.
3. Kho-Duffin J, Tao L-C, Cramer H, Catellier MJ, Irons D, Ng P. Cytologic diagnosis of malignant mesothelioma, with particular emphasis on the pithelial noncohesive cell type. Diagn Cytopathol 1999;20:57-62.
4. Ylagan LR, Zhai J. The value of ThinPrep and cytospin preparation in pleural effusion cytological diagnosis of mesothelioma and adenocarcinoma. Diagn Cytopathol 2005;32:137-144.
5. Politi E, Kandaraki C, Apostolopoulou C, Kyritsi T, Koutselini H. Immunocytochemical panel for distinguishing between carcinoma and reactive mesothelial cells in body cavity fluids. Diagn Cytopathol 2005;32:151-155.
6. Brockstedt U, Gulyas M, Dobra K, Dejmek A, Hjerpe A. An optimized battery of eight antibodies that can distinguish most cases of epithelial mesothelioma from adenocarcinoma. Am J Clin Pathol 2000;114:203-209.
7. Ordonez NG. Immunohistochemical diagnosis of epithelial mesotheliomas: A critical review of old markers, new markers. Hum Pathol 2002;33:953-967.
8. Moran CA, Wick MR, Suster S. The role of immunohistochemistry in the diagnosis of malignant mesothelioma. Semin Diagn Pathol 2000;114:203-209.
9. Doglioni C, Tos AP, Laurino L, et al. Calretinin: A novel immunocytochemical marker for mesothelioma. Am J Surg Pathol 1996;20:1037-1046.
10. Ordonez NG. Value of calretinin immunostaining in differentiating epithelial mesothelioma of the pleural from lung adenocarcinoma. Mod Pathol 1998;11:929-933.
11. Clover J, Oates J, Edwards C. Anti-cytokeratin 5/6: A positive marker for epithelioid mesothelioma. Histopathology 1997;31:140-143.
12. Ordonez NG. Value of cytokeratin 5/6 immunostaining in distinguishing epithelial mesothelioma of the pleural from lung adenocarcinoma. Am J Surg Pathol 1998;22:1215-1221.
13. Amin KM, Litzky LA, Smythe WR, Mooney AM. Wilms' tumor 1 susceptibility (WT1) gene products are selectively expressed in malignant mesothelioma. Am J Pathol 1995;146:344-356.
14. Foster MR, Johnson JE, Olson SJ, Allred AM. Immunohistochemical analysis of nuclear versus cytoplasmic staining of WT1 in malignant mesotheliomas and primary pulmonary adenocarcinomas. Arch Pathol Lab Med 2001;125:1316-1320.
15. Ordonez NG. Value of thyroid transcription factor-1, E-cadherin, BG8, WT1, CD44S immunostaining in distinguishing epithelial pleural mesotheloma from pulmonary and nonpulmonary adenocarcinoma. Am J Surg Pathol 2000;24:598-606.
16. Roberts F, Harper CM, Downie I, Burnett RA. Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies. Am J Clin Pathol 2001;116:253-262.
17. Abutaily AS, Addis BJ, Roche WR. Immunohistochemistry in the distinction between malignant mesothelioma and pulmonary adenocarcinoma: A critical evaluation of new antibodies. J Clin Pathol 2002;55:662-668.
18. Marks A, Sutherland DR, Bailey D, Iglesias J, Law H, Lei M, Yeger H, Banerjee D, Baumal R. Characterization and distribution of an oncofetal antigen (M2A antigen) expressed on testicular germ cell tumors. Br J Cancer 1999;80:569-578.
19. Kahn HJ, Bailey D, Marks A. Monoclonal antibody D2-40, a new marker of lymphatic endothelium, reacts with Kaposi's and a subset of angiosarcomas. Mod Pathol 2002;15:434-440.
20. Kahn HJ, Marks A. A new monoclonal antibody, D2-40, for detection of lymphatic invasion in primary tumors. Lab Invest 2002;82:1255-1257.
21. Chu AY, Litzky LA, Pasha TL, Acs G, Zhang PJ. Utility of D2-40, a novel meosthelial marker, in the diagnosis of malignant mesothelioma. Mod Pathol 2005;18:105-110.
22. Ordonez NG. D2-40 and podoplanin are highly specific and sensitive immunohistochemical markers of epithelioid malignant mesothelioma. Hum Pathol 2005;36:372-380.
23. Ordonez NG. Immunohistochemical diagnosis of epithelioid mesothelioma: An update. Arch Pathol Lab Med 2005;129:1407-1414.
24. Ordonez NG. In search of a positive immunohistochemical marker for mesothelioma: An update. Adv Anat Pathol 1998;5:53-60.
25. Jones DJ, Denning KL, Saad RS, et al. Diagnostic limitation of D2-40 in separating ovarian serous carcinoma from other metastatic carcinoma of the abdomen. Mod Pathol 2006;19:183A. (Abstract).
26. Ionescu DN, Masoudi H, Leung S, Gown AM, Gilks CB. Expression of mesothelial markers in ovarian cancers: A tissue microarray based study of 471 cases. Mod Pathol 2006;19:182A. (Abstract).
27. Kim MK, Kim S. Immunohistochemical profile of commen epithelial neoplasms arising in the kidney. Appl Immunohistochem Mol Morphol 2002;10:332-338.
28. Schwaller B, Celio MR, Hunziker W. Alternative splicing of calretinin mRNA leads to different forms of calretinin. Eur J Biochem 1995;230:424-30.
29. Tos AP, Doglioni C. Calretinin: A novel tool for diagnostic immunohistochemistry. Adv Anat Pathol 1998;5:61-66.
30. Carella R, Deleonardi G, D'Errico A, et al. Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: A study with logistic regression analysis. Am J Surg Pathol 2001;25:43-50.
31. Davidson B, Nielsen S, Christensen J, et al. The role of desmin and N-cadherin in effusion cytology: A comparative study using established markers of mesothelial and epithelial cells. Am J Surg Pathol 2001;25:1405-1412.
32. Ordóñez NG. The immunohistochemical diagnosis of mesothelioma: A comparative study of epithelioid mesothelioma and lung adenocarcinoma. Am J Surg Pathol 2003;35:697-710.
33. Leers MP, Aarts MM, Theunissen PH. E-cadherin and calretinin: A useful combination of immunochemical markers for differentiation between mesothelioma and metastatic adenocarcinoma. Histopathology 1998;32:209-216.
34. Blobel GA, Moll R, Franke WW, Kayser KW, Gould VE. The intermediate filament cytoskeleton of malignant mesotheliomas and its diagnostic significance. Am J Pathol 1985;121:235-247.
35. Chu PG, Weiss LM. Expression of cytokeratin 5/6 in epithelial neoplasms: An immunohistochemical study of 509 cases. Mod Pathol 2002;15:6-10.
36. Ordonez NG. The diagnostic utility of immunohistochemistry and electron microscopy in distinguishing between peritoneal epithelioid mesotheliomas and serous carcinomas: A comparative study. Mod Pathol 2006;19:34-48.
37. Chang K, Pai LH, Pass H, et al. Monoclonal antibody K1 reacts with epithelial mesothelioma but not with lung adenocarcinoma. Am J Surg Pathol 1992;16:259-268.
38. Oates J, Edwards C. HBME-1, MOC-31, WT1 and calretinin: An assessment of recently described markers for mesothelioma and adenocarcinoma. Histopathology 2000;36:341-347.
39. Kaufmann O, Dietel M. Thyroid transcription factor-1 is the superior immunohistochemical marker for pulmonary adenocarcinoma and large cell carcinomas compared to surfactant protein A and B. Histopathology 2000;36:8-16.
40. Di Loreto C, Puglisi F, Di Lauro V, Damante G. Beltrami CA. TTF-1 protein expression in pleural malignant mesotheliomas and adenocarcinomas of the lung. Cancer Lett 1998;124:73-78.
41. Wang BY, Gil J, Kaufman D, Gan L, Kohtz S, Burstein DE. P63 in pulmonary epithelium, pulmonary squamous neoplams and other pulmonary tumors. Hum Pathol 2002;33:921-926.
42. Pelosi G, Pasini F, Olsen Stenholm C, et al. P63 immunoreactivity in lung cancer: Yet another player in the development of squamous cell carcinomas? J Pathol 2002;198:100-109.